You are here
Taking a new path in pain management (Amended)
WITH one day to go before it trades on the Catalist, late-stage specialty pharmaceutical firm iX Biopharma has already caught the eyes of interested parties.
This might have something to do with the firm's niche, which lies in the development and commercialisation of
- CALL +65 6388 3838
- EMAIL email@example.com